Repatha and Praluent launches described by analyst as waste of money; AstraZeneca halts trial for cancer drug; health exchange choices dwindle
The neurology market is again attracting attention and investment from various — and at times unexpected — corners of the biopharma industry.
Voters are set to vote on Proposition 61, which would allow state agencies to pay the same prices for drugs that the VA department pays.
Now here comes the big question. Will the shareholders and directors of KaloBios and Allergan reward or punish their CEOs for what some may see as revenue-capping concessions?
Lawmakers ask for information about price of leukemia drug; Abbott writes down losses from Mylan stake; CVS Health focused on role as health brand
Merck doled out more than $2 million to target doctors in the first half of the year, while BMS spent only $863,000.
More drugmakers file lawsuits to prevent biosimilar competition; experimental dermatitis drug showeds promising results; pharma blames PBMs for price hikes
Patient advocacy groups stay silent in drug-pricing debate; Opdivo to be tested in combination with Nektar drug; 25% of FDA employees now work for industry
The organizations are using innovation competitions to challenge internal and external audiences with coming up with new ideas.
Amgen's drug is set to compete with AbbVie's Humira, which is the second-best selling drug in the U.S. in 2015.
Data analytics, relationship building, and improved patient support are the keys to differentiating your rare-disease drug brands, according to these four marketers.
Already ahead in race to first-line approval, could second-line domination be far behind for Keytruda?September 09, 2016
One analyst envisions how a first-line approval could set up Keytruda for success in other settings.
CEO Brent Saunders also said the drugmaker will not increase the price of drugs nearing patent expiration.
The intersection of data, technology, and medicine is rapidly changing how doctors practice, drug companies market, and patients engage with the healthcare system.
Fueled by innovation in new treatments, the underserved women's health market has begun to turn the proverbial corner. What took it so long?
The osteoporosis drug market is bracing for the advent of potentially game-changing treatments.
Amgen's osteoporosis drug Prolia is the category leader, projected to bring in $992 million in sales in 2016.
Only one new osteoporosis drug has been approved over the last six years.
Study finds estimated drug costs are often overstated; physician criticizes DTC ad for Opdivo; Merck HPV ads are criticized for being manipulative
The impending payer crackdown of the cost of MS drugs could portend the fate of other specialty drug markets, according to analysts.
Valeant had deployed roughly 100 additional sales reps this year to promote Xifaxan's indication in hepatic encephalopathy.
Novo Nordisk attributes slow growth to biosimilars, pricing; Dentsu acquires majority stake in Merkle; AZ lung cancer drug fails late-stage trial
Interest in oncology is on the rise as the blockbuster drug era breathes its last, and this has altered marketing in cancer care.
Despite the arrivals of new drugs, Genentech continues to be the market leader. Its drugs, Rituxan, Avastin, and Herceptin, are the category leaders, generating a total of $9.29 billion in sales.
While analysts predict a first-in-class appearance before the FDA by 2018, many obstacles have arisen.
The FDA declines to approve Novartis biosimilar; GSK partners with Apple's ResearchKit; drugmakers partner with Lyft for clinical trial participants
Drugmakers doled out $452 million to UK healthcare providers; GSK, Pfizer see big market in vaccines for expectant mothers; Shire ADHD drug meets endpoint
Novartis plans to launch five biosimilars; Making A Murderer directors will create project based on J&J investigation; Biogen plans to close or sell manufacturing plant
Hospitals struggle with high drug costs; the FDA approves new weight loss device; the ADA asks docs not to tweet, but they did anyway
BI launched a new gamified patient support program aimed at improving adherence to its COPD medication.
- Merck educates doctors about biosimilars, long before it will sell one in the U.S.
- 4 trends with the potential to change behavior in the patient journey
- 2016 Pharma Report: All the data in one place
- What do physicians think about biosimilars?
- Novartis considers new sales model for experimental cancer therapy